Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Stopped early · Phase 1/Phase 2
Conditions studied: Multiple Myeloma
In brief
The primary objectives are: Phase 1b: * To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of oprozomib given orally, once daily, on 2 different schedules. * To evaluate safety and tolerability Phase 2: * To estimate the overall response rate (ORR). * To evaluate safety and tolerability
Key facts
- Study ID
- NCT01832727
- Run by
- Amgen
- People needed
- 65
- Starts
- 2013-07-02
- Expected to finish
- 2019-06-25
- Last updated by the study team
- 2020-07-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
- H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
- University of Kansas Cancer Center and Medical Pavilion — Westwood, Kansas, United States
- Center for Cancer and Blood Disorders — Bethesda, Maryland, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Division of Hematology/ Oncology, UNC at Chapel Hill — Chapel Hill, North Carolina, United States
- Gabrail Cancer Center Research — Canton, Ohio, United States
- Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States
- CHRU, Hopital Huriez - Department of Hematology — Lille, France
- CHU Hotel Dieu - Service d'Hematologie Clinique — Nantes, France
- CHU de NANCY - Hopital de BRABOlS — Vandœuvre-lès-Nancy, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.